INTRODUCTIONMidazolam is widely used nowadays for sedation during elective endoscopy. Its sedative effect is mediated by the γ‐aminobutyric acid neurotransmitter system. Midazolam binds to the benzodiazepine receptor ligand in the brain and its inhibitory function results in decreased muscle tone and reduced anxiety. It has a faster onset of action and a shorter duration of effect than other benzodiazepines.Flumazenil, a competitive benzodiazepine antagonist, can reverse the sedative and hypnotic effects of midazolam. It is well known that flumazenil has the effect of reversing benzodiazepine‐induced sedation and reducing recovery time. Therefore, the drug is frequently administered after endoscopy with midazolam sedation in clinical practice. Sometimes it is also used in routine procedures, especially if time, space and nursing resources are limited.The use of flumazenil to reverse midazolam sedation after endoscopy is generally believed to be safe. However, many of the studies were not randomized controlled trials (RCTs), or RCTs with a too small number of participants to reach significance and the sample size was not calculated. In addition, some studies have shown that the use of flumazenil can increase the risk of adverse effects in patients who are then admitted to the emergency ward with impaired consciousness due to benzodiazepine
Journal of Digestive Diseases – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud